Human Genome Epidemiology Literature Finder
|
Records 1 - 9 (of 9 Records) |
| Query Trace: Fatigue and TP53[original query] |
|---|
| Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 May 26 (5): 1012-8. Fu S, Hou M M, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam |
| A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Nov . Ma Cynthia X, Luo Jingqin, Naughton Michael, Ademuyiwa Foluso O, Suresh Rama, Griffith Malachi, Griffith Obi L, Skidmore Zachary, Spies Nicholas C, Ramu Avinash, Trani Lee, Pluard Timothy, Nagaraj Gayathri, Thomas Shana N, Guo Zhanfang, Hoog Jeremy, Han Jing, Mardis Elaine R, Lockhart A Craig, Ellis Matthew |
| Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2018 6 24 (19): 4650-4661. Lim Ho Yeong, Merle Philippe, Weiss Karl Heinz, Yau Thomas, Ross Paul, Mazzaferro Vincenzo, Blanc Jean-Frédéric, Ma Yuk Ting, Yen Chia Jui, Kocsis Judit, Choo Su Pin, Sukeepaisarnjaroen Wattana, Gérolami René, Dufour Jean-François, Gane Edward J, Ryoo Baek-Yeol, Peck-Radosavljevic Markus, Dao Thong, Yeo Winnie, Lamlertthon Wisut, Thongsawat Satawat, Teufel Michael, Roth Katrin, Reis Diego, Childs Barrett H, Krissel Heiko, Llovet Josep |
| Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. European journal of cancer (Oxford, England : 1990) 2018 May 97 7-15. Cavalieri S, Perrone F, Miceli R, Ascierto P A, Locati L D, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi |
| Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer. OncoTargets and therapy 2020 8 13 6645-6650. Fang Shencun, Cheng Wanwan, Zhang Meiling, Yang Ruso |
| Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. Investigational new drugs 2020 2 38 (5): 1430-1441. Uy Geoffrey L, Assouline Sarit, Young Anne-Marie, Blotner Steven, Higgins Brian, Chen Lin-Chi, Yee Kar |
| Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific reports 2020 2 10 (1): 3080. Wang Yudong, Janku Filip, Piha-Paul Sarina, Hess Kenneth, Broaddus Russell, Liu Lidong, Shi Naiyi, Overman Michael, Kopetz Scott, Subbiah Vivek, Naing Aung, Hong David, Tsimberidou Apostolia M, Karp Daniel, Yao James, Fu Siqi |
| A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2021 12 163 19-26. Plummer Ruth, Dean Emma, Arkenau Hendrik-Tobias, Redfern Charles, Spira Alexander I, Melear Jason M, Chung Ki Y, Ferrer-Playan Jordi, Goddemeier Thomas, Locatelli Giuseppe, Dong Jennifer, Fleuranceau-Morel Patricia, Diaz-Padilla Ivan, Shapiro Geoffrey |
| Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042). Clinical cancer research : an official journal of the American Association for Cancer Research 2023 5 . Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, Noel Laudi, Mary W Redman, Jhanelle E Gray, David R Gandara, Karen Kel |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 29, 2023
- Content source: